World News: 13:00 GMT Wednesday 12th June 2019. [Soleno Therapeutics via Globe Newswire via SPi World News]
REDWOOD CITY, Calif., June 12, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced the appointment of Birgitte Volck, M.D., Ph.D., a veteran biopharmaceutical industry executive, to its Board of Directors, effective June 10, 2019. Dr. Volck’s appointment brings Soleno’s Board of Directors to seven members, six of whom are independent.
“We are extremely pleased to welcome Dr. Volck to our Board,” said Ernest Mario, Ph.D., Chairman of the Board of Directors of Soleno. “Dr. Volck’s extensive and diverse industry expertise, especially within rare diseases, will be essential to us as we continue to enroll patients into our Phase III DESTINY PWS trial evaluating Diazoxide Choline Controlled Release (DCCR) tablets for the treatment of Prader-Willi Syndrome. Moreover, Dr. Volck’s vast experience as an executive in both biotech and large pharma uniquely positions her to advise Soleno as we continue to grow our business and potentially evaluate DCCR in additional indications.”
Dr. Volck said, “I am excited to join Soleno’s Board of Directors at this transformational time in the Company’s history. I look forward to working with management and the rest of the Board as Soleno continues to advance DCCR as a potential treatment for those living with PWS and provide significant value to patients and caregivers.”
Since December 2018, Dr. Volck has served as the President R&D at AVROBIO Inc., a clinical stage gene therapy company. From 2016 to 2018, she served as head of Research and Development, Rare Diseases, for GlaxoSmithKline. From 2012 to 2016, Dr. Volck served as the Chief Medical Officer and Senior Vice President of Development at Swedish Orphan Biovitrum AB. Prior to this, from 2007 to 2012, she held various positions at Amgen Inc., including Executive Development Director, Bone, Neuroscience & Inflammation. From 2004 to 2007, Dr. Volck served as Nordic Medical Director and Project Director at Genzyme A/S, and from 2001 to 2004, she served as Head of Clinical Development and Medical Affairs at Pharmexa.
Dr. Volck currently serves as a director for Ascendis Pharma A/S. She also served as a director for Wilson Therapeutics AB from May 2017 to May 2018 until it was acquired by Alexion Pharmaceuticals for $850 million. Dr. Volck received her M.D. and Ph.D. degrees from Copenhagen University, Denmark.
For more information, please visit .
Globe Newswire: 13:00 GMT Wednesday 12th June 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.